

Set Name side by side	· 	Hit Count S	Set Name result set
DB=U	SPT,PGPB; PLUR=YES; OP=ADJ		
<u>L8</u>	L7 and ('non-hodgkin\$' or 'hodgkin\$')	28	<u>L8</u>
<u>L7</u>	('24-31' or '2b8')same (cd20 or cd40 or cd40L)	36	<u>L7</u>
<u>L6</u>	L5.clm.	3	<u>L6</u>
<u>L5</u>	(hodgkin\$ or 'non-hodgkin\$')same (cd20 or cd40 or cd40L) same (treat\$ or therap\$ or inhibit\$ or suppress\$ or prevent\$)	110	<u>L5</u>
<u>L4</u>	(hodgkin\$ or 'non-hodgkin\$') and (cd20 or cd40 or cd40L)	626	<u>L4</u>
<u>L3</u>	L2 and (cd20 or cd40L or cd40 adj ligand)	17	<u>L3</u>
<u>L2</u>	L1 and hodgkin\$	17	<u>L2</u>
<u>L1</u>	hanna-nabil\$	40	<u>L1</u>


Set Nam side by sid		Hit Count S	Set Name result set
DB=U	SPT,PGPB; PLUR=YES; OP=ADJ		
<u>L7</u>	('24-31' or '2b8')same (cd20 or cd40 or cd40L)	36	<u>L7</u>
<u>L6</u>	L5.clm.	3	<u>L6</u>
<u>L5</u>	(hodgkin\$ or 'non-hodgkin\$')same (cd20 or cd40 or cd40L) same (treat\$ or therap\$ or inhibit\$ or suppress\$ or prevent\$)	110	<u>L5</u>
<u>L4</u>	(hodgkin\$ or 'non-hodgkin\$') and (cd20 or cd40 or cd40L)	626	<u>L4</u>
<u>L3</u>	L2 and (cd20 or cd40L or cd40 adj ligand)	17	<u>L3</u>
<u>L2</u>	L1 and hodgkin\$	17	<u>L2</u>
<u>L1</u>	hanna-nabil\$	40	<u>L1</u>



Term	Documents
NON-HODGKIN.USPT,PGPB.	2172
NON-HODGKINS.USPT,PGPB.	390
HODGKIN.USPT,PGPB.	3824
HODGKINS.USPT,PGPB.	1303
(7 AND (NON-HODGKIN\$ OR HODGKIN\$)).USPT,PGPB.	28
(L7 AND ('NON-HODGKIN\$' OR 'HODGKIN\$')).USPT,PGPB.	28



DATE: Saturday, April 05, 2003 Printable Copy Create Case



Term	Documents
24-31.USPT,PGPB.	1546
24-31S	0
2B8.USPT,PGPB.	151
2B8S	0
CD20.USPT,PGPB.	1109
CD20S	0
CD40.USPT,PGPB.	1852
CD40S	0
CD40L.USPT,PGPB.	699
CD40LS.USPT,PGPB.	2
((2B8 OR 24-31) SAME (CD40L OR CD20 OR	36
CD40)).USPT,PGPB.	50
(('24-31' OR '2B8')SAME (CD20 OR CD40 OR	36
CD40L)).USPT,PGPB.	

Database:	US Patents Full-Text Database US Pre-Grant Publication Full-Text Database JPO Abstracts Database EPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins
Search:	L7 Refine Search Recall Text ← Clear
7	Search History

DATE: Saturday, April 05, 2003 Printable Copy Create Case

Generate Collection Print

Search Results - Record(s) 1 through 10 of 28 returned.

1. 20030026804. 17 Jul 02. 06 Feb 03. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody. Grillo-Lopez, Antonio J 424/144.1; A61K039/395.
2. 20030021781. 17 Jul 01. 30 Jan 03. Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Anderson, Darrell R., et al. 424/144.1; A61K039/395.
3. 20030012781 . 06 Jun 01. 16 Jan 03. Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof. Darrell, Anderson, et al. 424/131.1; 424/93.21 A61K048/00 A61K039/395.
☐ 4. <u>20030003097</u> . 02 Apr 02. 02 Jan 03. Recombinant antibodies coexpressed with GnTIII. Reff, Mitchell E., et al. 424/144.1; 435/334 530/388.22 A61K039/395 C12N005/06 C07K016/30.
5. <u>20020197256</u> . 14 Mar 02. 26 Dec 02. Combination therapy. Grewal, Iqbal. 424/144.1; 424/155.1 A61K039/395.
6. 20020197255. 25 Jul 01. 26 Dec 02. Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Anderson, Darrell R., et al. 424/144.1; 424/155.1 A61K039/395.
☐ 7. 20020128448. 22 Oct 01. 12 Sep 02. Variant IgG3 Rituxan and therapeutic use thereof. Reff, Mitchell E 530/387.3; 424/141.1 530/388.15 C07K014/46 A61K039/395.
8. 20020102208 . 01 Mar 99. 01 Aug 02. RADIOLABELING KIT AND BINDING ASSAY. CHINN, PAUL, et al. 424/1.53; 424/1.69 424/179.1 530/395 A61M036/14 A61K039/395 A61K039/40 A61K039/42 A61K039/44 C07K014/00 C07K017/00 C07K001/00 A61K051/00.
9. 20020058029. 18 Sep 01. 16 May 02. Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination. Hanna, Nabil. 424/131.1; 424/144.1 A61K039/395.
☐ 10. 20020039557. 20 Jun 01. 04 Apr 02. Treatment of B-cell associated diseases such as malignances and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination. White, Christine. 424/1.49; 424/143.1 A61K051/00 A61K039/395.
Generate Collection Print

Term	Documents
NON-HODGKIN.USPT,PGPB.	2172
NON-HODGKINS.USPT,PGPB.	390
HODGKIN.USPT,PGPB.	3824
HODGKINS.USPT,PGPB.	1303
(7 AND (NON-HODGKIN\$ OR HODGKIN\$)).USPT,PGPB.	28
(L7 AND ('NON-HODGKIN\$' OR 'HODGKIN\$')).USPT,PGPB.	28

Previous Page Next Page

Generate Collection Print

Search Results - Record(s) 11 through 20 of 28 returned.
11. 20020028178. 16 May 01. 07 Mar 02. Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/1.49; 424/143.1 A61K039/395 A61K051/00.
☐ 12. <u>20020009444</u> . 25 Apr 01. 24 Jan 02. Intrathecal administration of rituximab for treatment of central nervous system lymphomas. Grillo-Lopez, Antonio J. 424/142.1; 424/1.49 424/1.65 514/251 514/283 A61K051/10 A61K039/395 A61K051/04 A61K031/525 A61K031/475.
☐ 13. 20020009427. 23 Mar 01. 24 Jan 02. Methods of therapy for non-hodgkin's lymphoma. Wolin, Maurice J., et al. 424/85.2; 424/141.1 A61K039/395 A61K038/20.
☐ 14. 20020006404. 31 Jan 01. 17 Jan 02. Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/142.1; 424/155.1 A61K039/395.
☐ 15. <u>20020004587</u> . 20 Mar 01. 10 Jan 02. Multivalent antibodies and uses therefor. Miller, Kathy L., et al. 530/388.8; 424/143.1 435/325 435/334 536/23.5 C07K016/28 A61K039/395 C07H021/04 C12N005/06.
☐ 16. <u>20010036459</u> . 13 Apr 01. 01 Nov 01. Enhancement of antibody-mediated immune responses. Ravetch, Jeffrey V 424/143.1; 514/44 A61K039/395 A61K048/00.
☐ 17. 20010018041. 16 Apr 01. 30 Aug 01. Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy. Hanna, Nabil, et al. 424/1.49; 424/181.1 A61K039/395.
☐ 18. <u>6506383</u> . 14 Jun 99; 14 Jan 03. Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
☐ 19. <u>6455043</u> . 11 Aug 99; 24 Sep 02. Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody. Grillo-Lopez; Antonio J 424/155.1; 424/1.49 424/133.1 424/143.1 424/144.1 424/156.1 424/174.1. A61K039/395 A61K051/00.
20. 6451284. 26 Jul 00; 17 Sep 02. Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy. Raestetter; William, et al. 424/9.2; 424/1.11 424/1.49. A61K049/00.
Generate Collection Print

Term	Documents
NON-HODGKIN.USPT,PGPB.	2172
NON-HODGKINS.USPT,PGPB.	390
HODGKIN.USPT,PGPB.	3824
HODGKINS.USPT,PGPB.	1303
(7 AND (NON-HODGKIN\$ OR HODGKIN\$)).USPT,PGPB.	28
(L7 AND ('NON-HODGKIN\$' OR 'HODGKIN\$')).USPT,PGPB.	28

Previous Page Next Page

Generate Collection Print

Search Results - Record(s) 21 through 28 of 28 returned.

☐ 21. <u>6440418</u> . 08 Sep 97; 27 Aug 02. Methods of treating autoimmune diseases with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.2 530/388.2 530/388.7 530/388.75. A61K039/395 C07K016/28.
☐ 22. <u>6399061</u> . 07 Jun 95; 04 Jun 02. Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma. Anderson; Darrell R., et al. 424/133.1; 424/143.1 424/144.1 424/153.1 424/155.1 424/156.1 424/172.1 424/174.1 530/387.3 530/388.22 530/388.73 530/388.8 530/388.85 530/867. A61K039/395 C07K016/28 C07K016/30.
☐ 23. <u>6001358</u> . 07 Nov 95; 14 Dec 99. Humanized antibodies to human gp39, compositions containing thereof. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.7 530/388.7 530/388.75 536/23.53. A61K039/395 C07K016/28.
☐ 24. <u>5876718</u> . 27 Mar 98; 02 Mar 99. Methods of inducing T cell non-responsiveness to transplanted tissues and of treating graft-versus-host-disease with anti-gp39 antibodies. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/133.1 424/134.1 424/141.1 424/143.1 424/193.1 435/326 435/332 435/334 435/343 1530/388.2 530/388.2 530/388.7 530/388.7 530/388.75. A61K039/395 C07K016/28 C12N005/12.
☐ 25. <u>5843439</u> . 07 Jun 95; 01 Dec 98. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Anderson; Darrell R., et al. 424/133.1; 424/1.49 424/143.1 424/144.1 424/153.1 424/155.1 424/173.1 424/174.1 424/800 424/801 424/93.7 435/328 435/334 435/343.1 435/344 435/354 530/387.3 530/388.22 530/388.73 530/388.8 530/389.7 530/391.3 530/809 530/867. A61K039/00 A61K039/395 A61K051/00 C07K016/30.
☐ 26. <u>5776456</u> . 07 Jun 95; 07 Jul 98. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Anderson; Darrell R., et al. 424/133.1; 424/1.49 424/143.1 424/144.1 424/153.1 424/155.1 424/173.1 424/174.1 424/800 424/801 435/320.1 435/328 435/344 435/344.1 530/387.3 530/388.22 530/388.73 530/388.8 530/389.7 530/391.3 530/809 530/867. A61K039/395 A61K051/00 C07K016/28 C07K016/30.
☐ 27. <u>5747037</u> . 07 Jun 95; 05 May 98. Anti-GP39 antibodies. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 435/326 435/332 435/334 435/343 435/343.1 435/343.2 435/346 435/70.21 530/387.1 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A01K039/395 C07K016/28 C12N005/12.
☐ 28. <u>5736137</u> . 03 Nov 93; 07 Apr 98. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma. Anderson; Darrell R., et al. 424/133.1; 424/143.1 424/144.1 424/153.1 424/156.1 424/174.1 424/800 424/801 435/252.3 435/320.1 435/328 435/334 435/343.1 530/387.3 530/388.22 530/388.73 530/388.85 530/867. A61K039/395 C07K016/30 C12N001/21 C12N005/20.


Generate Collection

Print


Term	Documents
NON-HODGKIN.USPT,PGPB.	2172
NON-HODGKINS.USPT,PGPB.	390
HODGKIN.USPT,PGPB.	3824
HODGKINS.USPT,PGPB.	1303
(7 AND (NON-HODGKIN\$ OR HODGKIN\$)).USPT,PGPB.	28
(L7 AND ('NON-HODGKIN\$' OR 'HODGKIN\$')).USPT,PGPB.	28

Previous Page

Next Page




Term	Documents
NON-HODGKIN.USPT,PGPB.	2172
NON-HODGKINS.USPT,PGPB.	390
HODGKIN.USPT,PGPB.	3824
HODGKINS.USPT,PGPB.	1303
(7 AND (NON-HODGKIN\$ OR HODGKIN\$)).USPT,PGPB.	28
(L7 AND ('NON-HODGKIN\$' OR 'HODGKIN\$')).USPT,PGPB.	28




DATE: Saturday, April 05, 2003 Printable Copy Create Case

Set Name side by side		Hit Count	Set Name result set
DB=US	SPT,PGPB; PLUR=YES; OP=ADJ		
<u>L8</u>	L7 and ('non-hodgkin\$' or 'hodgkin\$')	28	<u>L8</u>
<u>L7</u>	('24-31' or '2b8')same (cd20 or cd40 or cd40L)	36	<u>L7</u>
<u>L6</u>	L5.clm.	3	<u>L6</u>
1.3	(hodgkin\$ or 'non-hodgkin\$')same (cd20 or cd40 or cd40L) same (treat\$ or therap\$ or inhibit\$ or suppress\$ or prevent\$)	110	<u>L5</u>
<u>L4</u>	(hodgkin\$ or 'non-hodgkin\$') and (cd20 or cd40 or cd40L)	626	<u>L4</u>
<u>L3</u>	L2 and (cd20 or cd40L or cd40 adj ligand)	17	<u>L3</u>
<u>L2</u>	L1 and hodgkin\$	17	<u>L2</u>
<u>L1</u>	hanna-nabil\$	40	<u>L1</u>



Term	Documents
"5843439".USPT,PGPB.	1
5843439S	0
"5843439".PNUSPT,PGPB.	1
(5843439.PN.).USPT,PGPB.	1



DATE: Saturday, April 05, 2003 Printable Copy Create Case

Set Name	Query	Hit Count	Set Name
side by side			result set
DB = USPT, PC	GPB; PLUR=YES; OP=ADJ		
<u>L3</u>	5843439.pn.	1	<u>L3</u>
<u>L2</u>	6410319.pn.	1	<u>L2</u>
<u>L1</u>	6001358.pn.	1	<u>L1</u>